VYNE Therapeutics
VYNE
54 hedge funds and large institutions have $64.3M invested in VYNE Therapeutics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 5 closing their positions.
2% more capital invested
Capital invested by funds: $63M → $64.3M (+$1.28M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.82% → 0.8% (-0.01%)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
2% less funds holding
Funds holding: 55 → 54 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.92M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$449K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$215K |
| 4 |
Renaissance Technologies
New York
|
+$125K |
| 5 |
State Street
Boston,
Massachusetts
|
+$98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.97M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$807K |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$632K |
| 4 |
DM
Deerfield Management
New York
|
-$446K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$275K |
VYNE Hedge Fund Activity: Q4 2019 in Review
54 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2019, worth a combined $64.3M — up 2% from $63M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VYNE and 4 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 19 added.
The largest buyer was Ameriprise, opening a new position worth an estimated $3.92M. The largest seller was OrbiMed, exiting entirely with an estimated $2.97M sold.
- 54 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2019, down from 55 in Q3 2019.
- Funds reported $64.3M of VYNE Therapeutics stock for Q4 2019, up 2% quarter-over-quarter.
- 4 funds opened new VYNE Therapeutics positions in Q4 2019 and 5 closed out, a net change of -1 holder.
- The largest VYNE Therapeutics buyer in Q4 2019 was Ameriprise, an estimated $3.92M added.
- The largest VYNE Therapeutics seller in Q4 2019 was OrbiMed, an estimated $2.97M sold.
Based on aggregated 13F filings for Q4 2019.